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Abstract
Our understanding of the events that occur in cancer progression
has been enhanced by the use of cell lines in vitro. Changes in
gene expression, induction of signalling, and cell motility can all be
investigated in this setting. However, other aspects of progression
can be revealed only in vivo, especially the interactions of tumour
cells with host cells and organ systems. In one such in vivo model,
described by McAllister and colleagues, it proved possible to
establish a novel function of an already well-characterised protein,
osteopontin, adding to its attractiveness as a target in cancer
therapy.
Laboratory-based cancer research involves making choices
about the experimental approach best suited to address the
question at hand. In vitro work has provided a vast amount of
relevant information with respect to tumour cell-specific
processes. For example, it has been possible to define
differences between tumours of varying malignancy and to
suggest candidate genes responsible for these differences
[1]. But such observations are only part of the story: in vivo
work provides a richer picture of the consequences of
presenting transformed cells to living organisms. The tumour
microenvironment is an essential element of the ‘success’ of
any cancer, and the ability to disrupt established growth
should be a valuable weapon in the treatment of solid
tumours. For research to progress beyond basic characteri-
sation of cancer cells, it is necessary to examine the inter-
action between tumour cells and the host organism.
In a recent paper, McAllister and colleagues [2] described
the use of a mouse model to examine the effect of the
presence of transformed cells of more than one type and the
interaction of these cells with the host organism. Different
tumour cell lines were injected into contralateral flanks of
nude mice. Cell lines designated as ‘instigators’ were capable
of inducing the growth of other cells – ‘responders’ – that
developed into larger and more viable tumours when
instigators were injected at the site opposite to the one at
which Matrigel or non-instigators (cell lines that seemed to
have no effect on responders) were injected. The instigators
did not affect the responders directly or migrate to responder
tumours but instead acted by activating and mobilising
specific bone marrow cells (BMCs) that moved to the
responder tumour. Furthermore, activated BMCs were able to
induce the growth of responding tumours when injected into
experimentally naive mice without the injection of instigators.
Comparison of the blood plasma of differently treated mice
suggested that osteopontin was responsible for this tumour
instigation. Instigating cells also increased the frequency of
lung metastases formed by circulating non-metastatic cells;
inhibition of osteopontin by short hairpin RNA abrogated this
effect. It was also demonstrated that the use of instigating
cells allowed the propagation of a human colon tumour
obtained from a surgical procedure.
The work described in the paper (including the supplemental
data) is exciting for many reasons. Osteopontin, a secreted
glycophosphoprotein, is known to be pleiotropic; it is capable
of inducing ‘the hallmarks of cancer’ described by Hanahan
and Weinberg [3] in breast cancer cells [4]. Osteopontin
expression has been observed in many cell lines that are
metastatic in nature [5]. However, these are largely examples
of an action of osteopontin on cancer cells themselves (with
the exception of its role in angiogenesis [6]). The work
described in this paper establishes a novel role for
osteopontin in recruiting host BMCs to create a sustaining
environment for tumour growth, in either a primary tumour or a
metastatic setting.
The use of this model will make it possible to screen other
molecules; osteopontin may not be the only molecule capable
of inducing instigation. Also, the effect of disruption of the
movement of BMCs to tumours can be assessed. The use of
BMCs expressing green fluorescent protein is particularly
valuable as it provides an immediate index of what cells a
tumour consists of.
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The work is also exciting because of the questions that
remain unanswered. The significance of the specificity of the
BMCs activated by osteopontin is unclear. It is noteworthy
that PC3 cells (a prostate cancer cell line) forcibly over-
expressing osteopontin develop many features of migratory
metastatic cells [7] but do not act as instigators in this model.
It is concluded that an additional factor, as yet unidentified, is
required for instigation. Although this is feasible, it is also the
case (but not discussed in the paper) that alternative splicing
and post-translational processing can alter the functional
range of osteopontin [8-10]. It seems necessary to carry out
further work to confirm that the PC3-derived osteopontin is
functionally comparable to that produced by other,
instigating, cell lines. In addition, activated macrophages can
secrete osteopontin that is functional in vitro [11]. Together,
this observation and the PC3 work described raise
interesting questions about the provenance of osteopontin
and the specific cell surface participants in osteopontin-
mediated processes in cancer.
This paper emphasises the involvement of osteopontin in
many aspects of tumour biology and extends our appreciation
of its repertoire. It also reinforces the argument that osteo-
pontin is an attractive target for cancer therapy development
[12,13]. Suppression of expression, or inhibition of down-
stream signalling pathways [14], of osteopontin could be a
potent method to inhibit tumour growth and check disease
progression. It may also be possible to grow clinically derived
samples, hitherto difficult to sustain, using osteopontin and
so use it as a vehicle in the downfall of cancer, which would
be a fitting role.
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